Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Navios Maritime Partners L.P. Announces Cash Distribution of $0.05 per Unit
-
Hawkins, Inc. Declares Quarterly Cash Dividend of $0.19 Per Share
-
Bausch Health Announces Third Quarter 2025 Results
-
Seer to Participate in Upcoming November Investor Conferences
-
Fluence Energy, Inc. Announces Fourth Quarter and Year-End 2025 Earnings Release Date, Conference Call and Webcast
-
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
-
Relevant Gold Completes Drilling at Apex, Confirms Orogenic Gold Model
-
PIH Health Announces Fiscal Year 2025-2026 Board of Directors
-
Tribal Leaders Applaud Senate Rejection of Barred Owl Resolution Threatening Forest and Wildlife Health
-
Align Technology Announces Third Quarter 2025 Financial Results
-
Leica Store & Gallery New York Presents "Within One Breath:" A Solo Exhibition by Matt Draper
-
Spruce Power to Release Third Quarter 2025 Results and Host Conference Call on November 11
-
Microsoft Cloud and AI Strength Drives First Quarter Results
-
GRAIL to Announce Third Quarter 2025 Financial Results
-
PatientNow Acquires Recura, the AI Growth Engine Powering Practice Growth
-
NewtekOne, Inc. Reports 3Q25 and Year-to-Date 2025 Basic and Diluted EPS of $0.68 and $0.67 and $1.57 and $1.54
-
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
-
IM Cannabis Announces CFO Departure
-
REGAL REXNORD REPORTS STRONG THIRD QUARTER 2025 FINANCIAL RESULTS
-
TTM Technologies, Inc. Reports Third Quarter 2025 Results
-
AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
-
FormFactor, Inc. Reports 2025 Third Quarter Results
-
Magnolia Oil & Gas Corporation Announces Third Quarter 2025 Results
-
AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025
-
Veru Announces Proposed Public Offering
-
Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
-
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
-
CPS Technologies Announces Third Quarter 2025 Financial Results
-
Papa Johns Declares Quarterly Dividend
-
YOOBIC Recognized in Six 2025 Gartner® Hype Cycle™ Reports
-
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
-
MIMEDX Announces Record Revenue for Third Quarter 2025
-
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
-
Princeton Bancorp Announces Third Quarter 2025 Results
-
Diamond Hill Appoints Diane Nordin to Its Board of Directors
-
Aware Reports Third Quarter and Nine-Month 2025 Financial Results
-
ZIEGLER CLOSES $107,525,000 FINANCING FOR FRIENDSHIP VILLAGE OF TEMPE (AZ)
-
Align Technology Announces New Innovations for iTero™ Digital Solutions, a Comprehensive Ecosystem That Includes Intraoral Scanners and Integrated Software Tools That Enhance the Chairside Patient E
-
Align Technology Announces ClinCheck® Live Plan That Automates Doctor-Ready Initial Invisalign® Treatment Plan in Minutes
-
Santa Clara Family Health Plan earns elevated rating from NCQA
-
Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
-
National Film and Sound Archive of Australia Selects Arcitecta’s Mediaflux to Power the Nation’s Audiovisual Heritage Strategy
-
MercadoLibre, Inc. Reports Third Quarter 2025 Financial Results
-
SilverSky Appoints Bruce Wirt as Chief Commercial Officer
-
Innovate NY Announces $4.2 Billion Annual Economic Output for New York City From Immigration Innovation Using Blockchain and Artificial Intelligence; Backs Andrew Cuomo for Mayor
-
Skyward Specialty Insurance Group Reports Third Quarter 2025 Results
-
NewHydrogen and Nuclear Power — A Perfect Pairing
-
Namibia Critical Metals Retains Renmark Financial Communications Inc.
-
FDA Issues Formal Guideline Waiving Clinical Efficacy Studies for Biosimilars, Confirming Professor Niazi's 15-Year Campaign to Cut Biologic Drug Costs
-
Kevin T. Taylor Is Rewriting the Rules of Leadership--One Pulpit, One Boardroom, One Life at a Time
